The Complement group, headed by Prof. Seppo Meri, has for long had an interest in sorting out how and why the complement system contributes to disease pathogenesis, how the system is controlled and ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...
Inflarx N.V. ( (IFRX) ) has released its Q3 earnings. Here is a breakdown of the information Inflarx N.V. presented to its investors. InflaRx N.V. is a biopharmaceutical company focused on developing ...
The complement system is part of the innate immune system, but can contribute to numerous diseases when it acts errantly, including kidney conditions. Purespring bottles up $105M series B to bring ...